Effect of albumin infusion on oxidative albumin modification and albumin binding capacity in chronic liver failure
- PMID: 38093476
- DOI: 10.1111/bcpt.13973
Effect of albumin infusion on oxidative albumin modification and albumin binding capacity in chronic liver failure
Abstract
Oxidative albumin modification and impaired albumin binding function have been described both in chronic liver failure and for therapeutic albumin solutions. The aim of the present study was to evaluate the effect of albumin infusion on redox state and binding function of circulating albumin. We studied 20 patients with cirrhosis who routinely received albumin infusions for prevention of post-paracentesis circulatory dysfunction or treatment of hepatorenal syndrome. We measured albumin fractions by redox state of cysteine-34 and albumin binding properties using dansylsarcosine as site II ligand. Therapeutic albumin solutions showed high contents of human nonmercaptalbumin-1 and human nonmercaptalbumin-2, exceeding the respective values in our patients with decompensated cirrhosis. An initial protocol for the first nine patients sampled at baseline, 24 h and 48 h after albumin infusion revealed no significant changes of oxidized albumin species or albumin binding properties. However, a modified protocol for the remaining 11 patients sampled at baseline, <1 h after and 24 h after albumin infusion revealed short-lived changes of oxidized albumin species while no changes in albumin binding properties were observed. In conclusion, therapeutic albumin infusion transiently changed albumin redox state but did not improve binding function of circulating albumin in chronic liver failure.
Keywords: albumin binding capacity; human mercaptalbumin; human nonmercaptalbumin-1; human nonmercaptalbumin-2; neutrophil function.
© 2023 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Similar articles
-
Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival.J Hepatol. 2013 Nov;59(5):978-83. doi: 10.1016/j.jhep.2013.06.013. Epub 2013 Jun 25. J Hepatol. 2013. PMID: 23811308
-
Human nonmercaptalbumin-2: a novel prognostic marker in chronic liver failure.Ther Apher Dial. 2014 Feb;18(1):74-8. doi: 10.1111/1744-9987.12024. Epub 2013 Mar 11. Ther Apher Dial. 2014. PMID: 24499087
-
Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure.Ther Apher Dial. 2009 Oct;13(5):431-6. doi: 10.1111/j.1744-9987.2009.00762.x. Ther Apher Dial. 2009. PMID: 19788461 Clinical Trial.
-
[The use of albumin infusion in decompensated liver cirrhosis].Ugeskr Laeger. 2002 Feb 25;164(9):1196-202. Ugeskr Laeger. 2002. PMID: 11899505 Review. Danish.
-
New Insights About Albumin and Liver Disease.Ann Hepatol. 2018 July - August ,;17(4):547-560. doi: 10.5604/01.3001.0012.0916. Ann Hepatol. 2018. PMID: 29893696 Review.
References
REFERENCES
-
- Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94(6):1493-1502. doi:10.1016/0016-5085(88)90691-9
-
- Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111(4):1002-1010. doi:10.1016/s0016-5085(96)70068-9
-
- Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61(2):396-407. doi:10.1016/j.jhep.2014.04.012
-
- Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417-2429. doi:10.1016/S0140-6736(18)30840-7
-
- Simard JR, Zunszain PA, Hamilton JA, Curry S. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol. 2006;361(2):336-351. doi:10.1016/j.jmb.2006.06.028
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources